OptiBiotix Health
plc
("OptiBiotix" or the "Company")
10
May 2024
Investor
update
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to
tackle obesity, cardiovascular disease,
diabetes and skincare, announces that Stephen
O'Hara, CEO of OptiBiotix will provide a live presentation to
investors via the Investor Meet Company platform
on Monday, 20 May 2024 at 2pm BST.
Stephen will use this opportunity to
update investors on OptiBiotix's commercial progress and
opportunity pipeline, and the Company's progress in e-commerce, and
in the USA, and Asia, and plans for the launch of second generation
products.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via the Investor Meet Company dashboard up until 9am the
day before the meeting or at any time during the live
presentation. Investors can sign up to
Investor Meet Company for free and add to
meet OptiBiotix.
To register for the presentation,
please use this link:
https://www.investormeetcompany.com/optibiotix-health-plc/register-investor
Investors who already
follow OptiBiotix on the Investor Meet Company platform
will automatically be invited.
For
further information, please contact:
|
OptiBiotix Health plc
|
www.optibiotix.com
|
|
Neil Davidson, Chairman
|
Contact via Walbrook
below
|
|
Stephen O'Hara, Chief
Executive
|
|
|
|
|
|
Peterhouse Capital Limited (Broker)
|
Tel: 020
7220 9797
|
|
Duncan Vasey / Lucy
Williams
|
|
|
|
|
|
Walbrook PR Ltd
|
Mob: 07876
741 001
|
|
Anna Dunphy
|
|
|
|
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI),
which was formed in March 2012, brings science to the development
of compounds which modify the human microbiome - the collective
genome of the microbes in the body - in order to prevent and manage
human disease and promote wellness.
OptiBiotix has an extensive R&D
programme working with leading academics in the development of
microbial strains, compounds, and formulations which are used as
active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements
with OptiBiotix to incorporate their human microbiome modulators
into a wide range of food products and drinks.
OptiBiotix is also developing its
own range of consumer supplements and health products. The
Company's current areas of focus include obesity, cardiovascular
health, and diabetes.
This communication is a "Reach"
announcement. Reach is a non-regulatory news service. By using this
service an issuer is confirming that the information contained in
this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.